Clarity Pharmaceuticals Ltd
Research Clarity Pharmaceuticals Ltd (CU6.AX) on Bullrun: market cap AUD 619.31M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCU6.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 619.31M
- Financial periodFY2026
Valuation Snapshot
latest market cap is AUD 619.31M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | n/a | n/a | n/a | -0.29 | n/a | n/a | n/a |
| FY2025 | n/a | -AUD 64.30M | -AUD 54.95M | n/a | -0.2 | AUD 47.68M | n/a | AUD 90.23M |
| FY2024 | n/a | -AUD 42.32M | -AUD 43.74M | n/a | -0.16 | AUD 47.90M | n/a | AUD 146.30M |
| FY2023 | n/a | -AUD 24.60M | -AUD 27.55M | n/a | -0.09 | AUD 31.21M | n/a | AUD 69.18M |
| FY2022 | n/a | -AUD 23.75M | -AUD 13.53M | n/a | n/a | AUD 55.34M | n/a | AUD 92.24M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-10 | AUD 619.31M | n/a | n/a | n/a |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer.
ETFs that hold Clarity Pharmaceuticals Ltd
US-listed ETFs
Clarity Pharmaceuticals Ltd is held by 13 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Core MSCI EAFE ETF (IEFA) | <0.01% | 0.07% |
| Vanguard FTSE Developed Markets Index Fund ETF Shares (VEA) | <0.01% | 0.03% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| iShares Core MSCI Total International Stock ETF (IXUS) | <0.01% | 0.07% |
| iShares MSCI EAFE Small-Cap ETF (SCZ) | 0.01% | 0.40% |
| Vanguard FTSE Pacific Index Fund ETF Shares (VPL) | <0.01% | 0.07% |
| Schwab International Small-Cap Equity ETF (SCHC) | 0.02% | 0.06% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Clarity Pharmaceuticals Ltd's market cap?
Clarity Pharmaceuticals Ltd's market capitalization is AUD 619.31M.
What does Clarity Pharmaceuticals Ltd do?
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer.